LS 75

metabolite of pirenzepine; structure given in first source

Also Known As:

LS-75

Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

1.	Neoplasms (Cancer) 11/01/2012 - "For therapeutic efficacy, inhibition of tumor growth in mice treated with 188Re-DXR-liposome-BBN was precisely controlled [mean growth inhibition rate (MGI) = 0.092] and had longer survival time [life-span (LS) = 86.96%] than those treated with anticancer drug 188Re-liposome-BBN (MGI = 0.130; LS = 75%), Lipo-Dox-BBN (MGI = 0.666; LS = 3.61%) and untreated control mice. "
2.	Liposarcoma 08/01/2005 - "The most common histopathologic type is that of atypical lipomatous tumor (ALT)/well-differentiated LS (75%). "